Mizuho Securities USA’s Starling Oncology STLN Stock Holding History

Mizuho Securities USA’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,000	Closed	-$262K	–	219
2020 Q4	$262K	Sell	25,000 -25,000	-50%	-$257K	0.02%	169
2020 Q3	$508K	Buy	+50,000	New	+$519K	0.04%	121

Other funds holding STLN

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Millennium Management

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

Mizuho Securities USA's STLN Position: Q1 2021 in Review

Mizuho Securities USA sold out of Starling Oncology (STLN) in Q1 2021, closing a stake of 25,000 shares — an estimated $262K sold.

Mizuho Securities USA first reported a position in STLN in Q3 2020 and held it in 2 quarters. The position peaked at $508K in Q3 2020. 50 funds tracked by Wall St. Rank hold STLN as of Q1 2021.

Mizuho Securities USA reported no remaining Starling Oncology position as of Q1 2021 after selling out during the quarter.
Mizuho Securities USA sold 25,000 Starling Oncology shares in Q1 2021, an estimated $262K.
Mizuho Securities USA first reported a position in Starling Oncology in Q3 2020 and held it in 2 quarters.
Mizuho Securities USA's Starling Oncology position peaked at $508K in Q3 2020.
50 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2021.

Based on Mizuho Securities USA's 13F filing for Q1 2021, filed 28 Apr 2021.